#ozempic
Novo Nordisk’s once‐weekly injectable, Ozempic (semaglutide), originally developed for type 2 diabetes, has increasingly attracted attention in Egypt, not just for its blood-sugar-lowering benefits, but for its marked weight‐loss effect too. Clinical trials involving more than 10,000 adults led to its launch in the country in late 2021, and local specialists have hailed its ability to both control blood sugar and reduce body weight, thereby lowering cardiovascular risk, which account for more than a third of total deaths in the…
